Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Fingolimod May Have Potential as AAV Treatment, Rat Study Indicates

Fingolimod (FTY720), a medication used to treat multiple sclerosis, also appears to ease many of the symptoms of ANCA-associated vasculitis (AAV), a new study in rats suggests. The study, “Sphingosine-1-phosphate receptor modulator FTY720 attenuates experimental myeloperoxidase-ANCA vasculitis in a T cell-dependent manner,” was published…

Trial Supports Long-term Maintenance Therapy With Rituximab

Continuing maintenance treatment with rituximab for long periods increases the likelihood that people with ANCA-associated vasculitis (AAV) remain in remission, without increasing the incidence or severity of adverse events, findings from a Phase 3 trial show. The study, “Long-Term Rituximab Use to Maintain Remission of…

AAV That Involves Central Nervous System Linked to More Active Disease, Chinese Study Suggests

In people with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), central nervous system involvement is associated with more active disease and peripheral nervous system involvement, a recent Chinese study suggests. The study, “Central nervous system involvement in patients with antineutrophil cytoplasmic antibody–associated vasculitis: a study of 29…